140 related articles for article (PubMed ID: 36515627)
21. Carcinoembryonic antigen, carbohydrate antigen 199 and carbohydrate antigen 724 in gastric cancer and their relationship with clinical prognosis.
Wang R; Zuo CL; Zhang R; Zhu LM
World J Gastrointest Oncol; 2023 Aug; 15(8):1475-1485. PubMed ID: 37663935
[TBL] [Abstract][Full Text] [Related]
22. Exploration of the application potential of serum multi-biomarker model in colorectal cancer screening.
Xu R; Shen J; Song Y; Lu J; Liu Y; Cao Y; Wang Z; Zhang J
Sci Rep; 2024 May; 14(1):10127. PubMed ID: 38698075
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic Value of Methylated
Xie L; Jiang X; Li Q; Sun Z; Quan W; Duan Y; Li D; Chen T
Front Oncol; 2018; 8():247. PubMed ID: 30013949
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.
Nilsson O; Johansson C; Glimelius B; Persson B; Nørgaard-Pedersen B; Andrén-Sandberg A; Lindholm L
Br J Cancer; 1992 Feb; 65(2):215-21. PubMed ID: 1739620
[TBL] [Abstract][Full Text] [Related]
25. [The value of serum human tumor protein P53 in colorectal cancer combined diagnosis and postoperative monitoring].
Fan P; Zhang Y; Deng F; Chen SH; Li M; Zhang Q
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2670-2673. PubMed ID: 28910954
[No Abstract] [Full Text] [Related]
26. Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer.
Luo H; Shen K; Li B; Li R; Wang Z; Xie Z
Oncol Lett; 2020 Jul; 20(1):742-750. PubMed ID: 32566000
[TBL] [Abstract][Full Text] [Related]
27. Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.
Wen Z; Huang Y; Ling Z; Chen J; Wei X; Su R; Tang Z; Wen Z; Deng Y; Hu Z
Dis Markers; 2020; 2020():4716793. PubMed ID: 33488842
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of monocyte to high-density lipoprotein cholesterol ratio and tumor markers in colorectal cancer and their relationship with clinicopathological characteristics.
Zhang X; Qin H; Tan X; Mo Y; Li Z; Huang G; Wei Z
World J Surg Oncol; 2023 Jul; 21(1):200. PubMed ID: 37420210
[TBL] [Abstract][Full Text] [Related]
29. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
30. [Expression and significance of serum microRNA-135a-5p level in colorectal cancer].
Wang QJ; Zhang HC; Shen XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):909-914. PubMed ID: 27998467
[No Abstract] [Full Text] [Related]
31. A predictive model combining fecal calgranulin B and fecal occult blood tests can improve the diagnosis of colorectal cancer.
Kim BC; Joo J; Chang HJ; Yeo HY; Yoo BC; Park B; Park JW; Sohn DK; Hong CW; Han KS
PLoS One; 2014; 9(9):e106182. PubMed ID: 25188229
[TBL] [Abstract][Full Text] [Related]
32. Serum tumor markers expression (CA199, CA242, and CEA) and its clinical implications in type 2 diabetes mellitus.
Meng M; Shi LL
World J Diabetes; 2024 Feb; 15(2):232-239. PubMed ID: 38464372
[TBL] [Abstract][Full Text] [Related]
33. Expression levels and diagnostic value of serum GDNF, CEA and CA199 in patients with colorectal carcinoma.
Jue W; Lulu L; Yan Z; Gu S
J Med Biochem; 2024 Apr; 43(2):250-256. PubMed ID: 38699694
[TBL] [Abstract][Full Text] [Related]
34. Methylated Septin 9 as a Promising Biomarker in the Diagnosis and Recurrence Monitoring of Colorectal Cancer.
Lu P; Zhu X; Song Y; Luo Y; Lin J; Zhang J; Cao Y; Huang Z
Dis Markers; 2022; 2022():7087885. PubMed ID: 35818587
[TBL] [Abstract][Full Text] [Related]
35. Estimating the probability of cancer with several tumor markers in patients with colorectal disease.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Oncology; 2004; 66(4):296-302. PubMed ID: 15218297
[TBL] [Abstract][Full Text] [Related]
36. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
[TBL] [Abstract][Full Text] [Related]
37. Correlation between Stool DNA-based SDC2 Methylation Tests Combined with Tumor Markers with Pathological Features in Colorectal Cancer.
Cheng Z; Wang Y; Wei W; Liu Y; Zhou Z
Clin Lab; 2023 Jul; 69(7):. PubMed ID: 37436377
[TBL] [Abstract][Full Text] [Related]
38. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
39. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
40. The Diagnosis Significance of Serum Cysteine Protease Inhibitors (CST4) in Colorectal Cancer.
Huang M; Yang Z; Ren J; Wang T; Chen D; Zhan Y; Le W; Deng S
Technol Cancer Res Treat; 2023; 22():15330338231164232. PubMed ID: 37122229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
